FIM

Still time to register! Join us for this e-conference with world-class experts happy to share their knowledge in #MPNsm with you

Revisiting diagnostic performances of serum erythropoïetin level and JAK2 mutation for polycythemias: guess which one is the best? Response in our study in more than 1000 patients @NabihMaslah @StephaneSgir @FimMpn #mpnsm 👇 onlinelibrary.wiley.com/shar…

So many new therapeutic options in development for #MPNsm #ASH21 Maybe time to redefine the precise role of phlebotomy as long term treatment for Polycythemia Vera? (il Guercino, Pinacoteca Nazionale di Bologna)

Idea for future meetings, a session named: "Promising preliminary, early, precursory, preparatory but amazing results of studies with less than 3 patients analyzed" (apologies for this one, don't even have the excuse of the jet lag...)

Very elegant study and presentation @AlbaRMeira @AdamMead_Oxford #ASH21 #MPNsm 👏👏👏 Luckily we don't see expansion of TP53 mutant clones in patients treated with #IFN suggesting that inflammatory effect is outweighted by other biological properties... #MiceAreNotSmallHumans

Sorry, but I'm already tired to hear in may presentations that adverse events are "tolerable" and "manageable"... from patients' point of view? Are we forced to use this language?

Superbe session @FimMpn sur SMP #mpnsm et dermatologie avec C. Lebbé @HopSaintLouis et JC Ianotto @CHRU_Brest, avec on l'espère des avancées à venir prochainement pour le traitement du prurit. Le suivi conjoint est en tous cas bénéfique pour les patients !

Tomorrow we'll have the pleasure to welcome @rschneiderlab for a plenary lecture during the 2021 Annual Scientific Meeting of @FimMpn. #mpnsm @valerie_ugo @isabelle_plo @StephaneSgir

On se prépare pour vous accueillir demain pour la Journée Scientifique 2021 du @FimMpn ! La matinée sera dédiée aux travaux du groupe et aux actualités dans les syndromes myéloprolifératifs #mpnsm @valerie_ugo @StephaneSgir @isabelle_plo @RautouE @LegrosLaurence

Merci à @marieclaire_fr pour ce focus sur la thrombocytémie essentielle, une maladie du sang peu connue faisant partie des syndromes myéloprolifératifs @FimMpn @ktourmente #mpnsm #VivreAvecUneNMP marieclaire.fr/thrombocytemi…

Great discussion about #COVID vaccination and treatment with interferon at #ELN21 : seems that patients on IFN don't have more adverse events and are likely to develop highest levels of antibodies, consistent with its immunostimulant activity @AndreasHochhaus & Tiziano Barbui

In the French @FimMpn registry with more than 1788 #MPN patients, almost 300 patients were treated with interferon: only 9% had #COVID19 and none of them developed a severe case. Preliminary results will be presented at the @sfhemato annual meeting on Thursday, stay tuned!

Important information that may help in the understanding of clonal evolution during interferon therapy in JAK2 and CALR mutated MPNs Great collaboration with @isabelle_plo @FimMpn @cerubidine doi.org/10.1182/blood.202101…

Une opportunité pour les patients de contribuer pour l'évaluation de cet inhibiteur de JAK2, qui pourrait être le 2ème disponible après le ruxolitinib. Participez à cette évaluation, votre avis doit compter, surtout à la lumière de ce qui s'est passé pour Besremi...